URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Laura Damme Biography and Net Worth

VP of TransMedics Group

Laura joins TransMedics with over 20 years of experience leading clinical affairs teams in the conduct and execution of medical device clinical studies which have resulted in successful approvals. Before joining TransMedics, Laura served as Director of Clinical Studies at Thoratec Corporation/Abbott, specializing in their Mechanical Circulatory Support business. Laura holds a Master of Public Health from the University of Michigan and received her nursing degree from Grand Valley State University.

How do I contact Laura Damme?: The corporate mailing address for Ms. Damme and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Laura Damme's contact information.
Has Laura Damme been buying or selling shares of TransMedics Group?: Laura Damme has not been actively trading shares of TransMedics Group over the course of the past ninety days. Most recently, Laura Damme sold 4,990 shares of the business's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $59.01, for a transaction totalling $294,459.90. Learn More on Laura Damme's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), and Anil Ranganath (Insider). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 44 times. They sold a total of 464,817 shares worth more than $52,965,578.65. The most recent insider tranaction occured on December, 2nd when insider Tamer I Khayal sold 1,084 shares worth more than $93,657.60. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 12/2/2024.

Laura Damme Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2022	Sell	4,990	$59.01	$294,459.90

Laura Damme Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $61.70

$59.72

$62.50

50 Day Range

MA: $88.42

$60.53

$134.24

2 Week Range

Now: $61.70

$59.72

$177.37

Volume

1,595,992 shs

Average Volume

1,055,467 shs

Market Capitalization

$2.07 billion

P/E Ratio

65.64

Dividend Yield

N/A

Beta

2.06